Skip to main content
Erschienen in:

01.07.2011 | Leitthema

Medizinische Therapie und Chemotherapie von neuroendokrinen Tumoren

verfasst von: Prof. Dr. M. Pavel

Erschienen in: Die Onkologie | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Neuroendokrine Tumoren (NET) stellen eine heterogene Erkrankung mit unterschiedlicher klinischer Präsentation und Prognose dar. Die Auswahl der medikamentösen Therapie orientiert sich in erster Linie an der Funktionalität, der Proliferationsrate (Grading) und dem Wachstumsverhalten des Tumors. Daneben sind Primärtumorsitz und die Tumorausdehnung von Bedeutung. Zu den verfügbaren Therapieoptionen gehören Somatostatinanaloga, Interferon α, neue molekular-zielgerichtete Therapien (z. B. Sunitinib, Everolimus) und die systemische Chemotherapie. Spezielle Entitäten erfordern zusätzliche Therapien (z. B. Protonenpumpeninhibitoren beim Gastrinom). Da keine komparativen Studien vorliegen, kann keine Therapiesequenz definiert werden und die verfügbaren Therapien werden oft sequenziell und individualisiert eingesetzt. Selten werden bei NET G1/G2-Tumorremissionen erzielt, häufig jedoch Wachstumsstabilisierungen, die nach vorausgegangener Tumorprogression als Therapieerfolg angesehen werden können. Das objektive Ansprechen auf systemische Chemotherapien ist dagegen bei neuroendokrinen Karzinomen (G3) hoch, jedoch oft von kurzer Dauer. Es existieren keine etablierten Reservetherapien.
Literatur
1.
Zurück zum Zitat Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24(1):28–47PubMedCrossRef Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24(1):28–47PubMedCrossRef
2.
Zurück zum Zitat Modlin IM, Pavel ME, Kidd M, Gustafsson BI (2010) Review Article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 31:169–188PubMed Modlin IM, Pavel ME, Kidd M, Gustafsson BI (2010) Review Article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 31:169–188PubMed
3.
Zurück zum Zitat Eriksson B, Klöppel G, Krenning E et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87:8–19PubMedCrossRef Eriksson B, Klöppel G, Krenning E et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87:8–19PubMedCrossRef
4.
Zurück zum Zitat Öberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973PubMedCrossRef Öberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973PubMedCrossRef
5.
Zurück zum Zitat Faiss S, Rath U, Mansmann U et al (1999) Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60:469–476PubMedCrossRef Faiss S, Rath U, Mansmann U et al (1999) Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60:469–476PubMedCrossRef
6.
Zurück zum Zitat Aparicio T, Ducreux M, Baudin E et al (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37:1014–1019PubMedCrossRef Aparicio T, Ducreux M, Baudin E et al (2001) Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37:1014–1019PubMedCrossRef
7.
Zurück zum Zitat Ducreux M, Ruszniewski P, Chayvialle JA et al (2000) The antitumoural effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumours. Am J Gastroenterol 95:3276–3281PubMedCrossRef Ducreux M, Ruszniewski P, Chayvialle JA et al (2000) The antitumoural effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumours. Am J Gastroenterol 95:3276–3281PubMedCrossRef
8.
Zurück zum Zitat Ricci S, Antonuzzo A, Galli L et al (2000a) Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 23:412–415PubMed Ricci S, Antonuzzo A, Galli L et al (2000a) Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 23:412–415PubMed
9.
Zurück zum Zitat Ricci S, Antonuzzo A, Galli L et al (2000b) Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 11:1127–1130PubMedCrossRef Ricci S, Antonuzzo A, Galli L et al (2000b) Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 11:1127–1130PubMedCrossRef
10.
Zurück zum Zitat Bajetta E, Procopio G, Catena L et al (2006) Lanreotide autogel every 6 weeks compared with Lanreotide microparticlesevery 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer 107:2474–2481PubMedCrossRef Bajetta E, Procopio G, Catena L et al (2006) Lanreotide autogel every 6 weeks compared with Lanreotide microparticlesevery 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer 107:2474–2481PubMedCrossRef
11.
Zurück zum Zitat Shojamanesh H, Gibril F, Louie A et al (2002) Prospective Study of the Antitumor Efficacy of Long-Term Octreotide Treatment in Patients with Progressive Metastatic Gastrinoma. Cancer 94:331–343PubMedCrossRef Shojamanesh H, Gibril F, Louie A et al (2002) Prospective Study of the Antitumor Efficacy of Long-Term Octreotide Treatment in Patients with Progressive Metastatic Gastrinoma. Cancer 94:331–343PubMedCrossRef
12.
Zurück zum Zitat Wymenga AN, Eriksson B, Salmela PI et al (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17(4):1111PubMed Wymenga AN, Eriksson B, Salmela PI et al (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17(4):1111PubMed
13.
Zurück zum Zitat Di Bartolomeo M, Bajetta E, Buzzoni R et al (1996) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Cancer 77(2):402–408CrossRef Di Bartolomeo M, Bajetta E, Buzzoni R et al (1996) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Cancer 77(2):402–408CrossRef
14.
Zurück zum Zitat Arnold R, Trautmann ME, Creutzfeldt W et al (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38(3):430–438PubMedCrossRef Arnold R, Trautmann ME, Creutzfeldt W et al (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38(3):430–438PubMedCrossRef
15.
Zurück zum Zitat Rinke A, Muller H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol 28:4656–4663CrossRef Rinke A, Muller H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol 28:4656–4663CrossRef
16.
Zurück zum Zitat Öberg K (2000) Interferon in the management of neuroendocrine GEP tumors. Digestion 62(Suppl 1):92–97PubMedCrossRef Öberg K (2000) Interferon in the management of neuroendocrine GEP tumors. Digestion 62(Suppl 1):92–97PubMedCrossRef
17.
Zurück zum Zitat Platanias LC (2005) Introduction: interferon signals: what is classical and what is nonclassical? J Interferon Cytokine Res 25(12):732PubMedCrossRef Platanias LC (2005) Introduction: interferon signals: what is classical and what is nonclassical? J Interferon Cytokine Res 25(12):732PubMedCrossRef
18.
Zurück zum Zitat Öberg K, Eriksson B (1991) The role of interferons in the management of carcinoid tumors. Acta Oncol 30:519–522PubMedCrossRef Öberg K, Eriksson B (1991) The role of interferons in the management of carcinoid tumors. Acta Oncol 30:519–522PubMedCrossRef
19.
Zurück zum Zitat Eriksson B, Öberg K (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32:203–208PubMedCrossRef Eriksson B, Öberg K (1993) An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 32:203–208PubMedCrossRef
20.
Zurück zum Zitat Faiss S, Pape UF, Bohmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696PubMedCrossRef Faiss S, Pape UF, Bohmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696PubMedCrossRef
21.
Zurück zum Zitat Arnold R, Rinke A, Klose KJ et al (2005) Octreotide vs. octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3(8):761–771PubMedCrossRef Arnold R, Rinke A, Klose KJ et al (2005) Octreotide vs. octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 3(8):761–771PubMedCrossRef
22.
Zurück zum Zitat Janson ET, Oberg K (1993) Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32:225–229PubMedCrossRef Janson ET, Oberg K (1993) Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32:225–229PubMedCrossRef
23.
Zurück zum Zitat Pavel ME, Baum U, Hahn EG et al (2006) Efficacy and tolerability of pegylated IFNalpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26:8–13PubMedCrossRef Pavel ME, Baum U, Hahn EG et al (2006) Efficacy and tolerability of pegylated IFNalpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26:8–13PubMedCrossRef
24.
Zurück zum Zitat Kulke MH, Lenz HJ, Meropol NJ et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26(20):3403–3410PubMedCrossRef Kulke MH, Lenz HJ, Meropol NJ et al (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26(20):3403–3410PubMedCrossRef
25.
Zurück zum Zitat Raymond E, Dahan L, Raoul J-L et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513PubMedCrossRef Raymond E, Dahan L, Raoul J-L et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513PubMedCrossRef
26.
Zurück zum Zitat Phan A, Yao JC, Fogelman DR et al (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 28:15 s, (suppl; abstr 4001)CrossRef Phan A, Yao JC, Fogelman DR et al (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 28:15 s, (suppl; abstr 4001)CrossRef
27.
Zurück zum Zitat Hobday T, Rubin J, Holen K (2007) MCO44 h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): a phase II consortium (P2 C) study. J Clin Oncol 25(Suppl 18 S):4504CrossRef Hobday T, Rubin J, Holen K (2007) MCO44 h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): a phase II consortium (P2 C) study. J Clin Oncol 25(Suppl 18 S):4504CrossRef
28.
Zurück zum Zitat Johannessen CM, Reczek EE, James MF et al (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102:8573–8578PubMedCrossRef Johannessen CM, Reczek EE, James MF et al (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102:8573–8578PubMedCrossRef
29.
Zurück zum Zitat Missiaglia E, Dalai I, Barbi S et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28(2):245–255PubMedCrossRef Missiaglia E, Dalai I, Barbi S et al (2010) Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 28(2):245–255PubMedCrossRef
30.
Zurück zum Zitat Duran I, Kortmansky J, Singh D et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148–1154PubMedCrossRef Duran I, Kortmansky J, Singh D et al (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148–1154PubMedCrossRef
31.
Zurück zum Zitat Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II trial. J Clin Oncol 26:4311–4318PubMedCrossRef Yao JC, Phan AT, Chang DZ et al (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II trial. J Clin Oncol 26:4311–4318PubMedCrossRef
32.
Zurück zum Zitat Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76PubMedCrossRef Yao JC, Lombard-Bohas C, Baudin E et al (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76PubMedCrossRef
33.
Zurück zum Zitat Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedCrossRef Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedCrossRef
34.
Zurück zum Zitat Pavel M, Hainsworth JD, Baudin E et al (2010) A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus+octreotide LAR vs. placebo+octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 21(Suppl 8):viii1–viii12, LBA8 Pavel M, Hainsworth JD, Baudin E et al (2010) A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus+octreotide LAR vs. placebo+octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). Ann Oncol 21(Suppl 8):viii1–viii12, LBA8
35.
Zurück zum Zitat Sun W, Lipsitz S, Catalano P et al (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897–4904PubMedCrossRef Sun W, Lipsitz S, Catalano P et al (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897–4904PubMedCrossRef
36.
Zurück zum Zitat Dahan L, Bonnetain F, Rougier P et al (2009) Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 16(4):1351–1361PubMedCrossRef Dahan L, Bonnetain F, Rougier P et al (2009) Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 16(4):1351–1361PubMedCrossRef
37.
Zurück zum Zitat Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMedCrossRef Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMedCrossRef
38.
Zurück zum Zitat Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771PubMedCrossRef Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771PubMedCrossRef
39.
Zurück zum Zitat Turner NC, Strauss SJ, Sarker D et al (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102(7):1106–1112PubMedCrossRef Turner NC, Strauss SJ, Sarker D et al (2010) Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 102(7):1106–1112PubMedCrossRef
40.
Zurück zum Zitat Fjallskog ML, Janson ET, Falkmer UG et al (2008) Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 88:53–58PubMedCrossRef Fjallskog ML, Janson ET, Falkmer UG et al (2008) Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology 88:53–58PubMedCrossRef
41.
Zurück zum Zitat Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2):268–275PubMedCrossRef Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2):268–275PubMedCrossRef
42.
Zurück zum Zitat Kulke MH, Stuart K, Earle CC et al (2006a) A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24:4044CrossRef Kulke MH, Stuart K, Earle CC et al (2006a) A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24:4044CrossRef
43.
Zurück zum Zitat Kulke MH, Stuart K, Enzinger PC et al (2006b) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumours. J Clin Oncol 24:401–406PubMedCrossRef Kulke MH, Stuart K, Enzinger PC et al (2006b) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumours. J Clin Oncol 24:401–406PubMedCrossRef
44.
Zurück zum Zitat Granberg D, Eriksson B, Wilander E et al (2001) Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 12(10):1383–1391PubMedCrossRef Granberg D, Eriksson B, Wilander E et al (2001) Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 12(10):1383–1391PubMedCrossRef
45.
Zurück zum Zitat Ekeblad S, Sundin A, Janson ET et al (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumours. Clin Cancer Res 13:2986–2991PubMedCrossRef Ekeblad S, Sundin A, Janson ET et al (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumours. Clin Cancer Res 13:2986–2991PubMedCrossRef
46.
Zurück zum Zitat Nilsson O, Van Cutsem E, Delle Fave G et al (2006) Frascati Consensus Conference; European Neuroendocrine Tumor Society: Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 84:212–215PubMedCrossRef Nilsson O, Van Cutsem E, Delle Fave G et al (2006) Frascati Consensus Conference; European Neuroendocrine Tumor Society: Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 84:212–215PubMedCrossRef
47.
Zurück zum Zitat Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62(Suppl 1):73–78PubMedCrossRef Rougier P, Mitry E (2000) Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 62(Suppl 1):73–78PubMedCrossRef
48.
Zurück zum Zitat Mani MA, Shroff RT, Jacobs C et al (2008) A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Oncol 26:(suppl; abstr 15550) Mani MA, Shroff RT, Jacobs C et al (2008) A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. J Clin Oncol 26:(suppl; abstr 15550)
49.
Zurück zum Zitat Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24(22):3548–3554PubMedCrossRef Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24(22):3548–3554PubMedCrossRef
50.
Zurück zum Zitat Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637–642PubMedCrossRef Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637–642PubMedCrossRef
51.
Zurück zum Zitat Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. doi:10.1002/cncr.26124 Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. doi:10.1002/cncr.26124
52.
Zurück zum Zitat McGory ML, Maggard MA, Kang H et al (2005) Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 48:2264–2271PubMedCrossRef McGory ML, Maggard MA, Kang H et al (2005) Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 48:2264–2271PubMedCrossRef
53.
Zurück zum Zitat Roy P, Chetty R (2010) Goblet cell carcinoid tumors of the appendix: An overview. World J Gastrointest Oncol 2(6):251–258PubMedCrossRef Roy P, Chetty R (2010) Goblet cell carcinoid tumors of the appendix: An overview. World J Gastrointest Oncol 2(6):251–258PubMedCrossRef
54.
Zurück zum Zitat Toumpanakis C, Standish RA, Baishnab E et al (2007) Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Dis Colon Rectum 50:315–322PubMedCrossRef Toumpanakis C, Standish RA, Baishnab E et al (2007) Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. Dis Colon Rectum 50:315–322PubMedCrossRef
55.
Zurück zum Zitat Pham TH, Wolff B, Abraham SC, Drelichman E (2006) Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. Ann Surg Oncol 13:370–376PubMedCrossRef Pham TH, Wolff B, Abraham SC, Drelichman E (2006) Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. Ann Surg Oncol 13:370–376PubMedCrossRef
56.
Zurück zum Zitat Saltz L, Trochanowski B, Buckley M et al (1993) Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 72:244–248PubMedCrossRef Saltz L, Trochanowski B, Buckley M et al (1993) Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 72:244–248PubMedCrossRef
57.
Zurück zum Zitat Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194PubMedCrossRef Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194PubMedCrossRef
58.
Zurück zum Zitat Eriksson B, Skogseid B, Lundqvist G et al (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65(9):1883–90PubMedCrossRef Eriksson B, Skogseid B, Lundqvist G et al (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 65(9):1883–90PubMedCrossRef
59.
Zurück zum Zitat Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21:36–38PubMedCrossRef Rivera E, Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21:36–38PubMedCrossRef
60.
Zurück zum Zitat Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P, Elias D, Lasser P, Baudin E 2004 The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40(4):515–20CrossRef Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P, Elias D, Lasser P, Baudin E 2004 The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer 40(4):515–20CrossRef
61.
Zurück zum Zitat Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumour activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944–948PubMedCrossRef Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumour activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944–948PubMedCrossRef
62.
Zurück zum Zitat Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232PubMedCrossRef Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232PubMedCrossRef
63.
Zurück zum Zitat Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedCrossRef Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedCrossRef
64.
Zurück zum Zitat Okita NT, Kato K, Takahari D et al (2011) Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 14(2):161–5. Epub 2011 Feb 16PubMedCrossRef Okita NT, Kato K, Takahari D et al (2011) Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer 14(2):161–5. Epub 2011 Feb 16PubMedCrossRef
65.
Zurück zum Zitat Olsen IH, Langer SW, Jepsen I et al (2011) First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience. Acta Oncol [Epub ahead of print] Olsen IH, Langer SW, Jepsen I et al (2011) First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience. Acta Oncol [Epub ahead of print]
Metadaten
Titel
Medizinische Therapie und Chemotherapie von neuroendokrinen Tumoren
verfasst von
Prof. Dr. M. Pavel
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 7/2011
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-011-2053-5

Weitere Artikel der Ausgabe 7/2011

Der Onkologe 7/2011 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.